Banque Cantonale Vaudoise Purchases 179 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Banque Cantonale Vaudoise grew its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,798 shares of the company’s stock after purchasing an additional 179 shares during the period. Banque Cantonale Vaudoise’s holdings in IDEXX Laboratories were worth $6,466,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Fifth Third Wealth Advisors LLC lifted its stake in shares of IDEXX Laboratories by 11.0% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 835 shares of the company’s stock valued at $422,000 after purchasing an additional 83 shares during the last quarter. Meeder Asset Management Inc. lifted its stake in shares of IDEXX Laboratories by 616.0% in the 3rd quarter. Meeder Asset Management Inc. now owns 179 shares of the company’s stock valued at $90,000 after purchasing an additional 154 shares during the last quarter. Quest Partners LLC lifted its stake in shares of IDEXX Laboratories by 4,059.4% in the 3rd quarter. Quest Partners LLC now owns 2,870 shares of the company’s stock valued at $1,450,000 after purchasing an additional 2,801 shares during the last quarter. Thrivent Financial for Lutherans raised its holdings in shares of IDEXX Laboratories by 150.6% in the third quarter. Thrivent Financial for Lutherans now owns 108,258 shares of the company’s stock worth $54,693,000 after buying an additional 65,050 shares during the period. Finally, Mutual of America Capital Management LLC raised its holdings in shares of IDEXX Laboratories by 0.6% in the third quarter. Mutual of America Capital Management LLC now owns 11,240 shares of the company’s stock worth $5,679,000 after buying an additional 68 shares during the period. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Trading Down 0.3 %

Shares of NASDAQ:IDXX opened at $419.83 on Tuesday. IDEXX Laboratories, Inc. has a 12-month low of $404.74 and a 12-month high of $583.39. The business’s fifty day simple moving average is $467.11 and its 200-day simple moving average is $482.44. The company has a market capitalization of $34.38 billion, a PE ratio of 40.49, a P/E/G ratio of 3.67 and a beta of 1.36. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.69 by $0.11. The firm had revenue of $975.50 million during the quarter, compared to analysts’ expectations of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.53 EPS. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on IDXX. JPMorgan Chase & Co. reduced their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Piper Sandler reiterated a “neutral” rating and issued a $435.00 price target (down from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Barclays reduced their price target on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. BTIG Research began coverage on IDEXX Laboratories in a report on Thursday, July 25th. They issued a “buy” rating and a $580.00 price target on the stock. Finally, Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a report on Thursday, October 10th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $552.38.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.